Jove
Visualize
Contáctanos

Videos de Conceptos Relacionados

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Cancer Vaccines01:30

Cancer Vaccines

929
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
929
Cancer Survival Analysis01:21

Cancer Survival Analysis

629
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
629
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.1K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

PROTEUS Trial the Day After: Practice Changing or Premature Escalation?

European urology oncology·2026
Same author

The UK's radiotherapy workforce shortage: a case for reform.

The Lancet. Oncology·2026
Same author

Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy.

World journal of urology·2026
Same author

Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols.

Future oncology (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Video Experimental Relacionado

Updated: Jan 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Cáncer de próstata

Valérie Fonteyne1, Alison Tree2, Elena Castro3

  • 1Department of Radiotherapy-Oncology, Ghent University Hospital, Ghent, Belgium.

Lancet (London, England)
|December 19, 2025
PubMed
Resumen
Este resumen es generado por máquina.

El tratamiento del cáncer de próstata ha avanzado significativamente, ofreciendo mejores resultados. Se dispone de nuevas terapias sistémicas, incluidos agentes dirigidos, para la enfermedad avanzada, junto con los tratamientos establecidos y la vigilancia activa para los casos indolentes.

Más Videos Relacionados

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.9K

Videos de Experimentos Relacionados

Last Updated: Jan 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.2K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer
07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.9K

Área de la Ciencia:

  • En el campo de la oncología
  • Urología

Sus antecedentes:

  • El cáncer de próstata es una de las principales causas de muerte relacionadas con el cáncer en todo el mundo.
  • Los avances recientes han transformado las estrategias de tratamiento del cáncer de próstata.
  • Comprender las opciones terapéuticas actuales es crucial para el manejo del paciente.

Objetivo del estudio:

  • Revisar la patología, el diagnóstico y el tratamiento del cáncer de próstata.
  • Para resaltar el panorama terapéutico en evolución.
  • Informar la toma de decisiones clínicas para los pacientes con cáncer de próstata.

Principales métodos:

  • Revisión de la literatura sobre la patología, el diagnóstico y el tratamiento del cáncer de próstata.
  • Análisis de las modalidades terapéuticas actuales y emergentes.
  • Discusión de la selección del tratamiento en función del estadio de la enfermedad y de los factores del paciente.

Principales resultados:

  • Se recomienda la vigilancia activa para el cáncer de próstata indolente.
  • Las terapias locales son efectivas para la enfermedad localizada.
  • Los tratamientos sistémicos, incluida la terapia de privación de andrógenos, la quimioterapia y los nuevos agentes como la terapia de radioligante Lu-177-PSMA y los inhibidores de PARP, son vitales para el cáncer de próstata avanzado y metastásico.

Conclusiones:

  • La toma de decisiones compartida, teniendo en cuenta la toxicidad y las preferencias de los pacientes, es esencial.
  • Se requiere más investigación para optimizar la secuencia y las combinaciones de tratamiento para el cáncer de próstata metastásico.
  • El panorama terapéutico para el cáncer de próstata continúa evolucionando, mejorando los resultados de los pacientes.